---
figid: PMC8351231__41416_2021_1519_Fig1_HTML
figtitle: Different signaling pathways involved in resistance to EGFR tyrosine kinase
  inhibitors (TKIs) driven by Protein Kinase C delta (PKCD) and receptor tyrosine
  kinase recycling
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC8351231
filename: 41416_2021_1519_Fig1_HTML.jpg
figlink: /pmc/articles/PMC8351231/figure/Fig1/
number: F1
caption: a PKCδ is a common mediator involved in EGFR TKI resistance. EGFR TKIs, like
  gefitinib, does not inhibit EGFR pY1173 and induce the formation of inactive EGFR
  heterodimers. The sustained pY1173 by EGFR heterodimer promotes the activation of
  PLCγ2 and PKCδ and downstream oncogenic signalling pathways. EGFR interacts with
  other RTKs, which are implicated in PKCδ and downstream oncogenic signalling pathway
  activation. b Increased pY374-PKCδ levels (regulated by the opposing actions of
  FER and PTPN14) increase the amount of RTKs on the cell surface. EGFR epidermal
  growth factor receptor, TKI tyrosine kinase inhibitor, Y tyrosine, p phosphorylation,
  PLCγ2 phospholipase γ2, PKCδ protein kinase Cδ, SHP2 Src-homology 2 domain-containing
  phosphatase 2, FER feline sarcoma-related, RAB5 Ras-associated binding protein 5,
  RTK receptor tyrosine kinase, CDCP1 CUB domain-containing protein 1.
papertitle: 'Coregulation of pathways in lung cancer patients with EGFR mutation:
  therapeutic opportunities.'
reftext: Rafael Rosell, et al. Br J Cancer. 2021 Dec 7;125(12):1602-1611.
year: '2021'
doi: 10.1038/s41416-021-01519-2
journal_title: British Journal of Cancer
journal_nlm_ta: Br J Cancer
publisher_name: Nature Publishing Group UK
keywords: Drug development | Predictive markers | Cancer therapeutic resistance
automl_pathway: 0.9633173
figid_alias: PMC8351231__F1
figtype: Figure
redirect_from: /figures/PMC8351231__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8351231__41416_2021_1519_Fig1_HTML.html
  '@type': Dataset
  description: a PKCδ is a common mediator involved in EGFR TKI resistance. EGFR TKIs,
    like gefitinib, does not inhibit EGFR pY1173 and induce the formation of inactive
    EGFR heterodimers. The sustained pY1173 by EGFR heterodimer promotes the activation
    of PLCγ2 and PKCδ and downstream oncogenic signalling pathways. EGFR interacts
    with other RTKs, which are implicated in PKCδ and downstream oncogenic signalling
    pathway activation. b Increased pY374-PKCδ levels (regulated by the opposing actions
    of FER and PTPN14) increase the amount of RTKs on the cell surface. EGFR epidermal
    growth factor receptor, TKI tyrosine kinase inhibitor, Y tyrosine, p phosphorylation,
    PLCγ2 phospholipase γ2, PKCδ protein kinase Cδ, SHP2 Src-homology 2 domain-containing
    phosphatase 2, FER feline sarcoma-related, RAB5 Ras-associated binding protein
    5, RTK receptor tyrosine kinase, CDCP1 CUB domain-containing protein 1.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Egfr
  - oph
  - thi
  - thiv
  - E(spl)malpha-BFM
  - de
  - Det
  - Dys
  - vi
  - Sh
  - bu
  - aop
  - Sur
  - Tie
  - Ras85D
  - InR
  - Arl1
  - Dcp-1
  - te
  - toe
  - pe
  - FER
  - dan
  - Tk
  - EGFR
  - APEH
  - COPA
  - ABCC8
  - CDCP1
  - PTPN14
  - TK1
  - TK2
---
